PFE: Pfizer Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 299,677.94
Enterprise Value ($M) 333,909.94
Book Value ($M) 77,463.00
Book Value / Share 13.81
Price / Book 3.87
NCAV ($M) -46,736.00
NCAV / Share -8.33
Price / NCAV -6.41

Profitability (mra)
Return on Invested Capital (ROIC) 0.21
Return on Assets (ROA) 0.16
Return on Equity (ROE) 0.36

Liquidity (mrq)
Quick Ratio 1.13
Current Ratio 1.39

Balance Sheet (mrq) ($M)
Current Assets 54,420.00
Assets 183,841.00
Liabilities 101,156.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 81,288.00
Operating Income 26,845.00
Net Income 21,979.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 32,580.00
Cash from Investing -22,546.00
Cash from Financing -9,816.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A State Street Corp 5.09 2.12
02-10 13G/A Vanguard Group Inc 8.29 3.87
02-01 13G/A BlackRock Inc. 7.30 3.28

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2022-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2022 ☐ TRANSITION REPORT PURSUANT TO S
2022-02-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA
2021-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2021 ☐ TRANSITION REPORT PURSUANT TO
2021-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2021 ☐ TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2022-05-25 2,016,152 20,809,432 9.69
2022-05-24 2,311,399 23,824,852 9.70
2022-05-23 1,880,829 19,531,215 9.63
2022-05-20 3,220,411 26,702,234 12.06

(click for more detail)

(click for list of largest short owners)

Similar Companies
NVS – Novartis AG OGN – Organon & Co.
PBH – Prestige Brands Holdings, Inc. PRGO – Perrigo Company PLC
QGEN – QIAGEN N.V.


Financial data and stock pages provided by
Fintel.io